W. Bradford  Smith net worth and biography

W. Smith Biography and Net Worth

Brad Smith has nearly 30 years of experience leading business and financial operations for public and private companies in the biotechnology and healthcare industry. During his career, Mr. Smith has been instrumental in raising nearly $1 billion in private and public equity and debt financing, has played a key role in business development and strategic planning functions and has successfully guided four companies through the IPO process. Prior to joining Homology, Mr. Smith served as Chief Financial Officer of Ocular Therapeutix, Inc., where he led the company’s strategic financings, including an IPO and subsequent follow-on offerings, and completed a development and commercialization deal with a major biopharmaceutical company. Previously, he served as CFO of five other companies, including OmniGuide Surgical, NeuroMetrix, Inc., SYNARC, PatientKeeper, Inc. and Focal, Inc. He is a member of the Board of Directors of Lyra Therapeutics and eGenesis. Mr. Smith holds a B.S. in Biology from Tufts University and an M.B.A. from the Whittemore School at the University of New Hampshire, and he became a Certified Public Accountant while working at Coopers & Lybrand.

What is W. Bradford Smith's net worth?

The estimated net worth of W. Bradford Smith is at least $0.00 as of January 2nd, 2020. Mr. Smith owns 12,000 shares of Homology Medicines stock worth more than $0 as of April 19th. This net worth estimate does not reflect any other investments that Mr. Smith may own. Learn More about W. Bradford Smith's net worth.

How do I contact W. Bradford Smith?

The corporate mailing address for Mr. Smith and other Homology Medicines executives is ONE PATRIOTS PARK, BEDFORD MA, 01730. Homology Medicines can also be reached via phone at (781) 301-7277 and via email at [email protected]. Learn More on W. Bradford Smith's contact information.

Has W. Bradford Smith been buying or selling shares of Homology Medicines?

W. Bradford Smith has not been actively trading shares of Homology Medicines during the past quarter. Most recently, W Bradford Smith sold 4,364 shares of the business's stock in a transaction on Wednesday, January 5th. The shares were sold at an average price of $1.89, for a transaction totalling $8,247.96. Learn More on W. Bradford Smith's trading history.

Who are Homology Medicines' active insiders?

Homology Medicines' insider roster includes Timothy Kelly (Insider), Albert Seymour (Insider), W. Smith (CFO), and Arthur Tzianabos (CEO). Learn More on Homology Medicines' active insiders.

Are insiders buying or selling shares of Homology Medicines?

During the last twelve months, insiders at the sold shares 4 times. They sold a total of 43,728 shares worth more than $13,375.58. The most recent insider tranaction occured on January, 9th when Director Arthur Tzianabos sold 26,074 shares worth more than $7,431.09. Insiders at Homology Medicines own 16.1% of the company. Learn More about insider trades at Homology Medicines.

Information on this page was last updated on 1/9/2024.

W. Bradford Smith Insider Trading History at Homology Medicines

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/5/2022Sell4,364$1.89$8,247.96View SEC Filing Icon  
1/2/2020Sell12,000$10.25$123,000.0012,000View SEC Filing Icon  
12/2/2019Sell12,000$8.11$97,260.0012,000View SEC Filing Icon  
11/29/2019Sell12,000$8.00$96,000.0012,000View SEC Filing Icon  
10/1/2019Sell12,000$8.70$104,340.00
9/3/2019Sell12,000$9.37$112,440.0012,000View SEC Filing Icon  
8/1/2019Sell12,000$8.69$104,220.0012,000View SEC Filing Icon  
7/1/2019Sell12,000$9.50$114,000.00View SEC Filing Icon  
6/3/2019Sell12,000$9.97$119,640.00View SEC Filing Icon  
See Full Table

W. Bradford Smith Buying and Selling Activity at Homology Medicines

This chart shows W Bradford Smith's buying and selling at Homology Medicines by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Homology Medicines Company Overview

Homology Medicines logo
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.49
Low: $0.30
High: $0.93

2 Week Range

Now: N/A

Volume

401,400 shs

Average Volume

390,307 shs

Market Capitalization

$54.33 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A